Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04751864 · ClinicalTrials.gov registry record · Phase 4
Brain Stimulation & Generalized Anxiety Study
A Phase 4 study of Anxiety and Generalized Anxiety Disorder, sponsored by ProofPilot.
- Active
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT04751864: Active Phase 4 study of Anxiety and Generalized Anxiety Disorder, sponsored by ProofPilot.
NCT04751864 is a Phase 4 study of Anxiety and Generalized Anxiety Disorder that is active but no longer recruiting, run by ProofPilot. The registered enrollment target is 150 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04751864, a Phase 4 study of Anxiety and Generalized Anxiety Disorder, is active but no longer recruiting, sponsored by ProofPilot.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.
Primary Outcome
The Beck is a 21 item self-reported scale measuring anxiety
Conditions Studied
Interventions
- DEVICE Cranial Electrotherapy Stimulator (CES) Device
Study Locations (1)
New York
- ProofPilot (Remote Virtual Trial) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-06-21 |
| Phase | Phase 4 |
What the registry record for NCT04751864 still lists
NCT04751864 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (66% lower).
The record links to 3 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Cranial Electrotherapy Stimulator (CES) Device is the first listed.
NCT04751864 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04751864 about?
NCT04751864 is a clinical study titled "Brain Stimulation & Generalized Anxiety Study". Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.
What is the current status of trial NCT04751864?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2020-10-15. Estimated completion is 2021-06-21.
What conditions does trial NCT04751864 study?
This clinical trial studies the following conditions: Anxiety, Generalized Anxiety Disorder, Generalized Anxiety.
What interventions are being tested in trial NCT04751864?
The interventions under investigation include: Cranial Electrotherapy Stimulator (CES) Device (DEVICE).
Who is sponsoring clinical trial NCT04751864?
This trial is sponsored by ProofPilot, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04751864 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04751864's enrollment target sits among peer trials
150 110th of 364 higher than 242 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
COMPLETED · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI